Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 6;20(4):414-424.
doi: 10.1093/ntr/ntx097.

Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

Li-Shiun Chen  1 , Laurie Zawertailo  2 , Thomas M Piasecki  3 , Jaakko Kaprio  4 , Marilyn Foreman  5 , Hannah R Elliott  6 , Sean P David  7 , Andrew W Bergen  8 , James W Baurley  8 , Rachel F Tyndale  9 , Timothy B Baker  10 , Laura J Bierut  1 , Nancy L Saccone  11 ; Genetics and Treatment Workgroup of the Society for Research on Nicotine and Tobacco (SRNT)
Affiliations
Review

Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

Li-Shiun Chen et al. Nicotine Tob Res. .

Abstract

This article outlines a framework for the consistent integration of biological data/samples into smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled Precision Medicine Initiative. Our goal is to encourage and provide support for treatment researchers to consider biosample collection and genotyping their existing samples as well as integrating genetic analyses into their study design in order to realize precision medicine in treatment of nicotine dependence.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Biological systems multi-omics from the genome, epigenome, transcriptome, proteome and metabolome to the phenome. SNP, single-nucleotide polymorphism; CNV, copy number variation; miRNA, micro RNA.
Figure 2.
Figure 2.
Example: Benefits of nicotine replacement therapy may vary by genetic marker. Blue: patients who benefit; Clear: patients who fail to benefit,, both studies of European Ancestry.
Figure 3.
Figure 3.
Pharmacogenomic trial designs, including retrospective, prospective stratified, and prospective screened. Source: Adapted from Lerman, IOM workshop presentation on November 17, 2010.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schroeder SA. New evidence that cigarette smoking remains the most important health hazard. N Engl J Med. 2013;368(4):389–390. - PubMed
    1. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–364. - PMC - PubMed
    1. Whiteford HA, Baxter AJ. The Global Burden of Disease 2010 study: what does it tell us about mental disorders in Latin America?Rev Bras Psiquiatr. 2013;35(2):111–112. - PubMed
    1. Knopik VS, Maccani MA, Francazio S, McGeary JE. The epigenetics of maternal cigarette smoking during pregnancy and effects on child development. Dev Psychopathol. 2012;24(4):1377–1390. - PMC - PubMed
    1. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341–350. - PubMed